NASDAQ : MRKR
Marker Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 16.34M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.92M |
| Enterprise Value | 3.59M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 16.67M |
| Shares Outstanding | 16.67M |
| Shares Change (YoY) | +73.22% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.82% |
| Owned by Institutions (%) | 16.08% |
| Float | 13.74M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.61 |
| Forward PS | 3.12 |
| PB Ratio | 1.34 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.03 |
| Quick Ratio | 5.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -76.87% |
| Return on Assets (ROA) | -40.47% |
| Return on Invested Capital (ROIC) | -52.43% |
| Return on Capital Employed (ROCE) | -78.12% |
| Weighted Average Cost of Capital (WACC) | 12.65% |
| Revenue Per Employee | $709,334 |
| Profits Per Employee | -$1.74M |
| Employee Count | 5 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -15,156 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -0.78% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.37 |
| Relative Strength Index (RSI) | 44.77 |
| Average Volume (20 Days) | 181,950 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 109,110 |
| Short Previous Month | 168,895 |
| Short % of Shares Out | 0.65% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 1.37 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.55M |
| Gross Profit | -5.26M |
| Operating Income | -9.50M |
| Pretax Income | -8.72M |
| Net Income | -8.71M |
| EBITDA | n/a |
| EBIT | -9.50M |
| Loss Per Share | -$0.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.33M |
| Total Debt | n/a |
| Net Cash | 11.33M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 12.17M |
| Book Value Per Share | 0.73 |
| Working Capital | 12.17M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -9.76M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -9.76M |
| FCF Per Share | -$0.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | -148.28% |
| Operating Margin | -267.95% |
| Pretax Margin | -245.94% |
| Profit Margin | -245.51% |
| EBITDA Margin | n/a |
| EBIT Margin | -267.95% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -73.22% |
| Shareholder Yield | -73.22% |
| Earnings Yield | -52.08% |
| FCF Yield | -59.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.87 |
| Price Target Difference | 778.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 187.15% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 27, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -40.36 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |